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Retinitis pigmentosa (RP) is the leading cause of hereditary blindness, and there is currently no available
treatment that can either signiﬁcantly slow the progression of this disease or restore lost vision.
Amphibians and birds exhibit different strategies for retinal regeneration, including the proliferation of
cells in the ciliary margin and transdifferentiation of the retinal pigment epithelium (RPE) and Muller
glia. The mammalian retina does not have the innate ability to regenerate damaged retina, but research is
actively exploring pathways that promote endogenous regeneration. Because the inner retinal archi-
tecture is largely preserved, even in advanced cases of RP, an alternative is to replace the degenerated
photoreceptor cells, thereby replenishing the photoreceptor population. The transplantation of embry-
onic stem cells, induced pluripotent stem cells, embryonic retinal progenitors (postmitotic photoreceptor
precursors), and hippocampal neuronal progenitors have been investigated for this purpose. The
encouraging results demonstrate the integration and possible functional connection between the
transplanted cells and the inner retinal circuitry of the host. In this review, we summarize recent
advancements in this ﬁeld and their potential for the treatment of RP and other retinal degenerations.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Retinitis pigmentosa (RP) refers to a group of inherited retinal
degenerations that result in severe visual impairment. Currently, 1.5
million people around the world are affected by RP, making it the
leading cause of hereditary blindness.1,2 Abnormalities have been
found in at least 179 genes (https://sph.uth.tmc.edu/retnet/sum-dis.
htm), and autosomal dominant, autosomal recessive, and X-linked
inheritance patterns have been described.3e7 RP is also associated
with several genetic syndromes.8 Despite the genetic heterogeneity
and wide variability in age of onset and severity, these syndromes
all share a similar phenotypic expression that is characterized by
the initial degeneration of rod followed by degeneration of the cone
and photoreceptors and the subsequent involvement of the inner
retina that leads to the loss of lamination, retinal vascular leakage,
invasion of retinal pigment epithelium (RPE) cells into the neural
retina, and, ﬁnally, the loss of ganglion cells.9,10
Currently there is no effective therapy that stops the progression
of RP or restores lost vision. Current medical management tech-
niques try to slow down the progression of retinal degeneration,
treat the various ocular complications that present such as cystoid
macular edema and posterior subcapsular cataract, and provideulevard, Louisville, KY 40202,
n).
e Ophthalmologic Society of Taiwpsychological support and genetic counseling to patients.11 Strat-
egies that slow the progression of these complications include
protection from light (because some retinopathies are light-
dependent)12 and vitamin A and E supplementation,13 however
these techniques remain controversial.
Exciting research is now being performed and new therapeutic
approaches are being explored. These approaches can be divided
into several broad groups according to the stage of the targeted
disease.14 The ﬁrst approach targets the retina when it still has
potentially functional photoreceptors and aims to correct the
underlying biochemical abnormalities through genetic therapy. This
approach can be further subdivided into gene augmentation ther-
apies, where a normal gene is inserted to replace a diseased gene,
and gene silencing therapies, where a mutated gene is inhibited
using ribozyme or RNA interference. An example of a gene
augmentation therapy is the correction of the retinoid cycle defect
of Leber’s congenital amaurosis, a severe form of RP that is caused by
a defect in the gene RPE65. Subretinal delivery of the normal RPE65
gene has been proven to produce sustained enhancement of the
functions of both the rods and cones in dogs and humans.15e17 The
drawback of genetic therapy is that it is mutation-speciﬁc, so its
success relies on knowing the precise genetic mutation and being
able to develop individualized therapy. Additionally, most genetic
defects are not null mutations, so the sole replacement of the
missing enzyme or protein may not be sufﬁcient to halt the
progression of retinal degeneration. A second approach is drugan. Published by Elsevier Taiwan LLC. All rights reserved.
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there is the potential to replenish the deﬁcit while the retina still has
functional potential.18,19 Recent studies suggest that chromophore
supplementation may achieve this result while avoiding drug
toxicity.20 The third approach is neuroprotection, which involves
slowing down the degeneration of the photoreceptors using neu-
rotrophic growth factors,21 thereby inhibiting pro-apoptotic path-
ways22 and providing viability factors.23 A fourth approach is
electric stimulation of the visual pathways, which is used when
there are few or no functional photoreceptors. The array of implants
currently being developed include cortical visual prostheses24 as
well as suprachoroidal,25 epiretinal,26,27 and subretinal implants
that stimulate the degenerated neural retina.28 The ﬁnal approach,
regenerative medicine, has recently reported important advances
that may allow new therapies that can treat this family of diseases.
2. Retinal cell regeneration
Amphibians have the ability to regenerate destroyed tissue,
unlike mammals; for example, newts can regenerate a new retina
from RPE. This process involves the dedifferentiation of the RPE and
the subsequent proliferation and generation of two layersda pig-
mented and a nonpigmented layerdthat results in a functional
retina with normal architecture.29 This process is referred to as
transdifferentiation.30 Embryonic chick eyes are able to undergo
a similar transdifferentiation process, even though the retinal
progenitorsmaintain their polarity, thereby resulting in an inverted
retina that has a photoreceptor layer along the inner surface of the
retina near the vitreous and a ganglion cell layer that faces outward.
Transdifferentiation in chicks can also arise from Muller glia, but
only selected populations of retinal neurons are derived from these
cells.31 Fish have a similar ability to undergo transdifferentiation,
regenerating a retina from Muller glia that can proliferate to form
a blastema-like population next to the site of injury.32
Amphibians and ﬁsh also have a growth zone at the junction of
the ciliary epithelium and the retina that is referred to as the ciliary
marginal zone (CMZ). These animals are able to maintain their
peripheral retina throughout life by adding concentric rings of
neurons that originate from the stem cells at the CMZ.32 Similarly,
the embryonic chick retina can also undergo regeneration through
cells within the CMZ. In contrast, the vast majority of the retinal
cells in birds are produced during the ﬁrst 10 days of embryonic
development, but the CMZ is not spontaneously active during the
posthatching phase.31
As already mentioned, the mammalian retina has only a limited
capacity for neuronal regeneration. The Muller glia in the mature
retina becomes reactive and hypertrophic following injury,33 and
only a few of these cells are able to reenter the mitotic cycle.34
Although some progenitor genes can be activated after injury and
mitotic provocation, many genes are not reexpressed, which
explains at least in part the limited regeneration potential of the
mammalian retina.35 The age of the animal seems to determine the
proliferative ability of the Muller glia, which declines shortly after
birth.36 However, a portion of the Muller glia may exhibit stem cell
properties and become spontaneously immortalized under speciﬁc
conditions in vitro.37 While these ﬁndings are encouraging, the
functional integration of these cells remains uncertain. Human
ciliary epithelial cells are able to express retinal progenitor genes,
but these cells do not differentiate into neurons in vitro.38
3. Cell replacement strategies
Because endogenous retinal regeneration is limited in humans,
the idea of replacing dysfunctional or dead photoreceptors with
stem cells is currently being explored (Fig. 1). The mature centralnervous system can effectively synapse with retinal grafts. When
rat eyes are transplanted into young rat brains, they are able to
connect to the visual pathway and respond to light.39 Because the
eye is an immune-privileged organ where neural grafts can survive
long-term,40 several laboratories are exploring the transplantation
of stem cells into replace damaged photoreceptors after intravitreal
or subretinal placement. Stem cell migration and integration into
the outer retina (i.e., the outer nuclear layer [ONL]) after intravitreal
transplantation has been observed in the developing rodent retina
but not in healthy adults.41 Although intravitreally injected stem
cells appear to have some ability to migrate to the ONL, a subretinal
transplant would present signiﬁcant advantages for integration.
The rationale for stem cell transplantation after the onset of
retinal degeneration is based on the existence of a functional inner
retinal network, even when advanced disease is present. In a study
on postmortem eyes from patients with advanced RP, only 4% of the
photoreceptors remained (in comparison with normal retinas), but
66% of the bipolar cells and 28% of the ganglion cells were still
present.42 The observation that the inner neural retinal network
remains intact in cases of advanced disease, and is presumably
functional during the early stages of hereditary retinal degeneration,
has given impetus to studies on photoreceptor replacement. Intact
photoreceptor sheets have been transplanted into the subretinal
space and have been proven as safe for use in humans.43 These
sheets have the theoretical advantage of a pre-established mono-
layer morphology, but they develop rosettes after transplantation
that restrict the integration of these cells.44 Retinal spheres have
also been transplanted into the subretinal space, but they tend to
clump, which also inhibits integration into the host retina.45
Enzymatically dissociated cell suspensions have been injected
into the subretinal space in order to avoid these problems. Murine
retinal embryonic tissue has been dissociated and demonstrated
both integration into the ONL and differentiation into photore-
ceptor cells. The generation of inner and outer segments in these
cells, with synapses that connect to the host’s bipolar cells, is
associated with the restoration of light sensitivity as measured by
pupillometry and extracellular ﬁeld potential recordings of the
ganglion cell layer.46 The age of the donor appears to be a critical
factor in these experiments because neither progenitor cells nor
adult photoreceptors have shown a similar ability to restore func-
tion. Only newly postmitotic photoreceptors have been shown to
result in photoreceptor restoration.47
Human embryonic stem cells (hESC) are pluripotentdi.e., they
have the ability to differentiate into any cell type in the body and
are a promising source for use in retinal transplantation. Cells
derived from hESC can be differentiated into either cone or rod
photoreceptors. hESC have been transplanted into Crx-/- miceda
model of Leber’s congenital amaurosisdand have demonstrated
functional integration and photoreceptor differentiation with
recovery of electroretinogram (ERG) to light stimuli.48 RPE derived
from hESC was recently transplanted into patients with age-related
macular degeneration. On a very short follow-up, no signs of
tumorigenicity, ectopic tissue formation, or rejection were noted.49
An alternative approach used hippocampal progenitor cells as
a potential source of retinal neurons. The hippocampus is a site of
active neurogenesis in adult mice; however, expanded hippo-
campal progenitor cells fail to show opsin expression after
transplantation.50
Because of the limited access to human embryonic tissue, retinal
progenitors have been expanded in vitro and differentiated into
photoreceptors.51 These cells can integrate into degenerated rodent
retina and develop photoreceptor-like morphology capable of
expressing recoverin, rhodopsin, and cone opsin.52 Unfortunately,
very few of these cells actually integrate into the rodent retina or
develop both an inner and outer segment.
Fig. 1. Schematic diagram of the origins of various stem cells. Adult somatic cells can be reprogrammed into iPSC, which differentiate into photoreceptors. ESC isolated from
a blastocyst can also differentiate into photoreceptors. Embryonic retinal cells, as well as ciliary epithelial cells, have also been used to replenish photoreceptor populations. These
cells can be transplanted into either the vitreous cavity or subretinal space. iPSC: induced pluripotent stem cells; ESC: embryonic stem cells.
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political and ethical issues that arise from the use of human
embryonic tissue, involves the use of induced pluripotent stem cells
(iPSC). These are somatic cells that can be forced to overexpress
a group of pluripotency genes, resulting in stem cell-like charac-
teristics in these cells. iPSC have been differentiated in vitro into rods
and transplanted into a swine model of retinal degeneration. They
were able to integrate into the damaged retina, express rhodopsin,
and exhibit projections that resemble the outer segments.53 iPSC-
derived photoreceptor precursors have also been transplanted into
Rho-/- adultmice and been shown to integrate into the outer nuclear
layer and increase the scotopic ERG response.54 The ability to
differentiate iPSC into rods offers the possibility of using these cells
to recreate genetically diseased rod photoreceptors from human
patients so that the underlyingmechanisms of the disease, aswell as
its potential for reversal, can be studied.
Despite the signiﬁcant advancements that have been made in
the ﬁeld of photoreceptor regeneration in the past few years, many
challenges still remain. Large animal models of RP are an invaluable
tool for assessing stem cell therapies. Although the rodent eye is
very valuable for providing insight into the underlyingmechanisms
of retinal degeneration, as well as possible therapeutic alternatives,
the signiﬁcant differences between rodent and human eyes inhibit
the translation of these observations into clinical therapies. New
animal models of RP in swine55 and rabbit56 provide several
advantages over the rodent: Namely, the larger size of the eyes in
these species allows the development of surgical techniques that
are applicable to humans, more complete electrophysiological
testing is possible through the use of both full-ﬁeld and multifocalelectroretinography, and the existence of cone-rich visual streaks
allows the study of the sequential effects of the disease on rod and
cone photoreceptors.4. Conclusions
Recent advances in stem cell therapy for the treatment of RP and
other hereditary retinal degenerations present new and exciting
therapeutic pathways; however, which of these approaches will
prove most useful is still unknown. It remains plausible that
photoreceptor replacement through the use of stem cells will have
a future role in the treatment of these diseases.References
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